Baricitinib Hits 16-Week Marks for Atopic Dermatitis - MD Magazine

Baricitinib Hits 16-Week Marks for Atopic Dermatitis  MD Magazine

The JAK inhibitor previously approved for rheumatoid arthritis has reported early primary endpoint outcomes in its ongoing phase 3 trial.



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases